, Cancer immunotherapies targeting the PD-1 signaling pathway, 2019.
Neurological complications of immune checkpoint inhibitors: what happens when you "take the brakes off" the immune system, Ther Adv Neurol Disord, vol.11, p.1756286418799864, 2018. ,
Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies, JAMA Neurology, vol.74, issue.10, p.1216, 2017. ,
Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors, Journal of Thoracic Oncology, vol.12, issue.11, pp.1626-1635, 2017. ,
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis, Oncologist, vol.22, issue.6, pp.709-718, 2017. ,
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup ?, Annals of Oncology, vol.28, issue.suppl_4, pp.119-142, 2017. ,
Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature, European Journal of Cancer, vol.73, pp.1-8, 2017. ,
Neurological toxicities associated with immune-checkpoint inhibitors, Curr Opin Neurol, vol.30, issue.6, pp.659-668, 2017. ,
Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature, Ann Oncol, vol.28, issue.2, pp.377-385, 2017. ,
Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC, Journal of Thoracic Oncology, vol.11, issue.9, pp.1511-1521, 2016. ,
Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer, JAMA Oncol, 2018. ,
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline, J Clin Oncol, vol.36, issue.17, pp.1714-1768, 2018. ,